Tricida Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • Tricida's estimated annual revenue is currently $10.9M per year.(i)
  • Tricida received $100.0M in venture funding in March 2018.
  • Tricida's estimated revenue per employee is $417,462
  • Tricida's total funding is $499M.
  • Tricida's current valuation is $491.1M. (January 2022)

Employee Data

  • Tricida has 26 Employees.(i)
  • Tricida grew their employee count by -42% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its late-stage investigational product candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). We are led by a management team with an accomplished and proven track record in discovering, developing and commercializing new therapeutics, with extensive experience in building successful companies around strong science and unmet medical needs. We recently completed a successful Initial Public Offering and our stock is listed on the Nasdaq Global Select Market under the symbol TCDA. We are expanding our existing group of exceptionally talented and well-motivated colleagues to develop and commercialize our first-in-class drug candidate, TRC101. Tricida's shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients. Highly Competitive Compensation and Benefits

keywords:Analytics,Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Tricida News

2022-04-20 - Analysts Expect Tricida, Inc. (NASDAQ:TCDA) Will Post ...

Zero analysts have provided estimates for Tricida's earnings. The highest EPS estimate is ($0.58) and the lowest is ($0.70). Tricida reported...

2022-04-19 - Should You Buy Tricida Inc (TCDA) Stock on Tuesday?

TCDA receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator. Sentiment Score - ,bullish. Tricida Inc has a Bullish sentiment...

2022-03-22 - Tricida Announces Fourth Quarter and Full Year 2021 ...

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a...

2019-09-04 - Tricida (TCDA) Announces Submission of New Drug ...

Tricida (TCDA) Announces Submission of New Drug Application for Veverimer for Treatment of Metabolic Acidosis in Patients with CKD.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Tricida Funding

DateAmountRoundLead InvestorsReference
2016-07-26$55.0MCLongitude CapitalArticle
2017-11-09$57.5MDWellington Management Company LLPArticle
2018-03-05$100.0MUndisclosedHercules CapitalArticle